Sickle Cell Anemia

Icagen Reports First Quarter 2007 Financial Results

Published in Blood Weekly, May 24th, 2007

Icagen, Inc. (NASDAQ: ICGN) reported today its financial results for the first quarter of 2007. For the first quarter of 2007, the Company reported revenues of $2.0 million and a net loss of $6.5 million. As of March 31, 2007, cash and cash equivalents totaled $40.3 million.

Seth Hetherington, M.D., SVP of Clinical and Regulatory Affairs noted, "We have experienced both accomplishments and challenges in the early part of 2007. While making excellent progress in several of our programs, as earlier reported we terminated our Phase III study of senicapoc for the reduction of crisis rate in patients with sickle cell disease ("SCD") on the basis of our independent Data...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2007-05-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry